Your browser doesn't support javascript.
loading
Rare coding variants in CHRNB2 reduce the likelihood of smoking.
Rajagopal, Veera M; Watanabe, Kyoko; Mbatchou, Joelle; Ayer, Ariane; Quon, Peter; Sharma, Deepika; Kessler, Michael D; Praveen, Kavita; Gelfman, Sahar; Parikshak, Neelroop; Otto, Jacqueline M; Bao, Suying; Chim, Shek Man; Pavlopoulos, Elias; Avbersek, Andreja; Kapoor, Manav; Chen, Esteban; Jones, Marcus B; Leblanc, Michelle; Emberson, Jonathan; Collins, Rory; Torres, Jason; Morales, Pablo Kuri; Tapia-Conyer, Roberto; Alegre, Jesus; Berumen, Jaime; Shuldiner, Alan R; Balasubramanian, Suganthi; Abecasis, Gonçalo R; Kang, Hyun M; Marchini, Jonathan; Stahl, Eli A; Jorgenson, Eric; Sanchez, Robert; Liedtke, Wolfgang; Anderson, Matthew; Cantor, Michael; Lederer, David; Baras, Aris; Coppola, Giovanni.
Affiliation
  • Rajagopal VM; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Watanabe K; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Mbatchou J; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Ayer A; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Quon P; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Sharma D; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Kessler MD; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Praveen K; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Gelfman S; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Parikshak N; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Otto JM; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Bao S; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Chim SM; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Pavlopoulos E; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Avbersek A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Kapoor M; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Chen E; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Jones MB; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Leblanc M; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Emberson J; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Collins R; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Torres J; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Morales PK; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Tapia-Conyer R; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Alegre J; Experimental Research Unit from the Faculty of Medicine (UIME), National Autonomous University of Mexico (UNAM), Mexico, Mexico.
  • Berumen J; Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Mexico.
  • Shuldiner AR; Experimental Research Unit from the Faculty of Medicine (UIME), National Autonomous University of Mexico (UNAM), Mexico, Mexico.
  • Kang HM; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Marchini J; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Stahl EA; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Jorgenson E; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Sanchez R; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Liedtke W; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Anderson M; Regeneron Genetics Center, Tarrytown, NY, USA.
  • Cantor M; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Lederer D; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Baras A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
  • Coppola G; Regeneron Genetics Center, Tarrytown, NY, USA.
Nat Genet ; 55(7): 1138-1148, 2023 07.
Article de En | MEDLINE | ID: mdl-37308787
ABSTRACT
Human genetic studies of smoking behavior have been thus far largely limited to common variants. Studying rare coding variants has the potential to identify drug targets. We performed an exome-wide association study of smoking phenotypes in up to 749,459 individuals and discovered a protective association in CHRNB2, encoding the ß2 subunit of the α4ß2 nicotine acetylcholine receptor. Rare predicted loss-of-function and likely deleterious missense variants in CHRNB2 in aggregate were associated with a 35% decreased odds for smoking heavily (odds ratio (OR) = 0.65, confidence interval (CI) = 0.56-0.76, P = 1.9 × 10-8). An independent common variant association in the protective direction ( rs2072659 ; OR = 0.96; CI = 0.94-0.98; P = 5.3 × 10-6) was also evident, suggesting an allelic series. Our findings in humans align with decades-old experimental observations in mice that ß2 loss abolishes nicotine-mediated neuronal responses and attenuates nicotine self-administration. Our genetic discovery will inspire future drug designs targeting CHRNB2 in the brain for the treatment of nicotine addiction.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Trouble lié au tabagisme / Nicotine Type d'étude: Etiology_studies / Prognostic_studies Limites: Animals / Humans Langue: En Journal: Nat Genet Sujet du journal: GENETICA MEDICA Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Trouble lié au tabagisme / Nicotine Type d'étude: Etiology_studies / Prognostic_studies Limites: Animals / Humans Langue: En Journal: Nat Genet Sujet du journal: GENETICA MEDICA Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique